Withdrawal of Infliximab or Concomitant Immunosuppressant Therapy in Patients With Crohn's Disease on Combination Therapy (SPARE): A Multicentre, Open-Label, Randomised Controlled Trial

被引：0
|
作者：
Louis, E.
Resche-Rigon, M.
Laharie, D.
机构：
来源：
DISEASES OF THE COLON & RECTUM | 2023年 / 66卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1520 / 1521
页数：2
相关论文
共 50 条
  • [41] Shunting outcomes in communicating hydrocephalus: protocol for a multicentre, open-label, randomised controlled trial
    Sun, Tong
    Cui, Wenyao
    Yang, Jingguo
    Yuan, Yikai
    Li, Xuepei
    Yu, Hang
    Zhou, Yicheng
    You, Chao
    Guan, Junwen
    BMJ OPEN, 2021, 11 (08):
  • [42] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease REPLY
    Colombel, Jean Frederic
    Sandborn, William J.
    Rutgeerts, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (11): : 1087 - 1088
  • [43] Prone versus lateral position in acute hypoxemic respiratory failure patients with HFNO therapy: study protocol for a multicentre randomised controlled open-label trial
    Zhou, Xixin
    Luo, Xiaoqing
    Li, Qin
    Chen, Guihua
    Tong, Jin
    Deng, Wang
    TRIALS, 2023, 24 (01)
  • [44] Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
    Colombel, Jean Frederic
    Sandborn, William J.
    Reinisch, Walter
    Mantzaris, Gerassimos J.
    Kornbluth, Asher
    Rachmilewitz, Daniel
    Lichtiger, Simon
    D'Haens, Geert
    Diamond, Robert H.
    Broussard, Delma L.
    Tang, Kezhen L.
    van der Woude, C. Janneke
    Rutgeerts, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (15): : 1383 - 1395
  • [45] Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease
    Hirten, Robert
    Longman, Randy S.
    Bosworth, Brian P.
    Steinlauf, Adam
    Scherl, Ellen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (12): : 1737 - 1738
  • [46] Prone versus lateral position in acute hypoxemic respiratory failure patients with HFNO therapy: study protocol for a multicentre randomised controlled open-label trial
    Xixin Zhou
    Xiaoqing Luo
    Qin Li
    Guihua Chen
    Jin Tong
    Wang Deng
    Trials, 24
  • [47] Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
    Buhl, Sine Schnoor
    Steenholdt, Casper
    Brynskov, Jorn
    Thomsen, Ole Ostergaard
    Bendtzen, Klaus
    Ainsworth, Mark Andrew
    BMJ OPEN, 2014, 4 (12):
  • [48] Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension
    Hyams, Jeffrey
    Walters, Thomas D.
    Crandall, Wallace
    Kugathasan, Subra
    Griffiths, Anne
    Blank, Marion
    Johanns, Jewel
    Lang, Yinghua
    Markowitz, James
    Cohen, Stanley
    Winter, Harland S.
    Veereman-Wauters, Gigi
    Ferry, George
    Baldassano, Robert
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 651 - 662
  • [49] Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma
    Wen, Patrick Yung
    Rodon, Jordi A.
    Mason, Warren
    Beck, Joseph T.
    DeGroot, John
    Donnet, Valerie
    Mills, David
    El-Hashimy, Mona
    Rosenthal, Mark
    ESMO OPEN, 2020, 5 (04)
  • [50] Hyperbaric oxygen therapy for perianal Crohn's disease: An open-label pilot study
    Taylor, K.
    Heerasing, N.
    Cheung, W.
    Scarff, C.
    Mccann, C.
    Fock, A.
    Sparrow, M.
    Jakobovits, S.
    Ward, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 94 - 94
12345